Novartis Europharm Ltd Withdraws Its Marketing Authorization Application For Rasival (aliskiren/valsartan)

Published: Sep 20, 2010

Medical News Today -- The European Medicines Agency has been formally notified by Novartis Europharm Ltd of its decision to withdraw its application for a centralised marketing authorisation for the medicine Rasival (aliskiren/valsartan), 150/160 mg and 300/320 mg film-coated tablets.

Back to news